HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Aspeslet, L. J. Articles by Yatscoff, R. W. Search for Related Content PubMed PubMed Citation Articles by Aspeslet, L. J. Articles by Yatscoff, R. W. Related Collections Evidence Based Laboratory Medicine and Test Utilization Drug Monitoring and Toxicology

Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral^® and Sandimmune® formulations

¹ Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada.

² Sandoz Canada Inc.
^a Address correspondence to this author at: Department of Laboratory Medicine & Pathology, University of Alberta Hospitals, 8840–112 St., Edmonton, AB, Canada T6G 2B7. Fax 403-492-8599; email randy.yatscoff{at}ualberta.ca

The new oral formulation of cyclosporine (CsA), Neoral® (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sandimmune^® (CsA-S) formulation. The present study examines the effect of assay methodology on variability in blood concentrations and PK parameters for renal transplant patients receiving CsA-N and CsA-S and whether this variation is reduced with CsA-N. The results show that interindividual variations in PK parameters for patients receiving CsA-N were less than those for patients receiving CsA-S. Both blood concentrations and dose of CsA better correlated with abbreviated (4-h) AUC after administration of CsA-N. For both CsA-S and CsA-N, blood concentrations at 4 h postdose exhibited the best correlation with AUC. All samples were analyzed by three common procedures: HPLC, RIA, and fluorescence polarization immunoassay (FPIA). There were no significant differences observed in blood concentrations or PK parameters obtained from FPIA and RIA. HPLC results, however, were lower because of specificity of this method for the parent drug. The assay methodology did not have an effect on interindividual variability, indicating that the cross-reactivity of metabolites in commonly used immunoassays for CsA does not contribute to the PK variability observed in renal transplant patients.

Key Words: indexing terms: pharmacokinetics • therapeutic drug monitoring • metabolite cross-reactivity • renal transplants • immunosuppression • radioimmunoassay • high-performance liquid chromatography • fluorescence polarization immunoassay

The following articles in journals at HighWire Press have cited this article:

				J. D. Chester, S. P. Joel, S. L. Cheeseman, G. D. Hall, M. S. Braun, J. Perry, T. Davis, C. J. Button, and M. T. Seymour Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1125 - 1132. [Abstract] [Full Text] [PDF]

				W. Steimer Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific? Clin. Chem., March 1, 1999; 45(3): 371 - 381. [Abstract] [Full Text] [PDF]

				L. D. Bowers Analytical goals in therapeutic drug monitoring Clin. Chem., February 1, 1998; 44(2): 375 - 380. [Abstract] [Full Text] [PDF]